Crispr Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $892 | $865 | $35,000 | $602 |
Gross Profit | -48,861 | -56,644 | 35,000 | -10,551 |
EBITDA | -202,657 | -143,688 | -59,746 | -105,391 |
EBIT | -207,257 | -148,424 | -64,588 | -110,191 |
Net Income | -208,549 | -135,996 | -37,311 | -85,942 |
Net Change In Cash | 892 | 865 | 35,000 | 602 |
Free Cash Flow | -113,997 | -54,153 | -50,285 | -107,132 |
Cash | 197,132 | 235,184 | 298,257 | 225,670 |
Basic Shares | 87,069 | 85,938 | 85,464 | 85,235 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $35,000 | $371,206 | $436 | $913,081 |
Gross Profit | -75,250 | 240,956 | -109,814 | 913,081 |
EBITDA | -447,307 | -202,701 | -648,989 | 391,481 |
EBIT | -466,566 | -222,538 | -673,161 | 373,528 |
Net Income | -366,252 | -153,610 | -650,175 | 377,661 |
Net Change In Cash | 35,000 | 371,206 | 436 | 913,081 |
Cost of Revenue | -715,804 | -245,513 | ||
Free Cash Flow | -144,675 | -272,345 | -532,929 | 457,267 |
Cash | 298,257 | 389,477 | 211,885 | 923,031 |
Basic Shares | 84,359 | 79,220 | 77,746 | 80,393 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | -$2.40 |
2025-03-31 | -$1.58 |
2024-12-31 | -$0.44 |
